Plague (Bubonic Plague)

Subscribe to Selected New Research on Plague

1062 relevant articles (76 outcomes, 83 trials/studies) found for this Disease

Description: An acute infectious disease caused by YERSINIA PESTIS that affects humans, wild rodents, and their ectoparasites. This condition persists due to its firm entrenchment in sylvatic rodent-flea ecosystems throughout the world. Bubonic plague is the most common form.

Also Known As:

Bubonic Plague; Pneumonic Plague; Plague, Bubonic; Meningeal Plagues; Plague, Meningeal; Plague, Pneumonic; Plague, Pulmonic; Plagues, Meningeal; Plagues, Pneumonic; Plagues, Pulmonic; Pneumonic Plagues; Pulmonic Plagues; Meningeal Plague; Pulmonic Plague

Relationship Network

Disease Context: Research Results

Bacterial Infections and Mycoses

Bacterial Infections: 6393

Gram-Negative Bacterial Infections: 230

Enterobacteriaceae Infections: 25

Yersinia Infections: 100

Plague: 1062

Related Diseases

1.	Infection
2.	Plague (Bubonic Plague)
3.	Tularemia
4.	Anthrax
5.	Brucellosis (Malta Fever)

Experts

1.	Titball, Richard W: 8 articles (03/2007 - 01/2003)
2.	Shcherbaniuk, A I: 7 articles (01/2006 - 01/2000)
3.	Ryzhko, I V: 7 articles (01/2006 - 01/2000)
4.	Tsuraeva, R I: 6 articles (01/2004 - 01/2000)
5.	Williamson, E D: 5 articles (10/2004 - 01/2000)
6.	Adamovicz, Jeffrey J: 4 articles (08/2008 - 08/2005)
7.	Freytag, Lucy C: 4 articles (11/2007 - 03/2005)
8.	Clements, John D: 4 articles (11/2007 - 03/2005)
9.	Chanteau, S: 4 articles (12/2000 - 01/2000)
10.	Powell, Bradford S: 3 articles (05/2007 - 08/2005)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Plague:

1.	AntigensIBA 07/20/2001 - "A sub-unit vaccine based on the F1- and V-antigens is highly effective against both bubonic and pneumonic plague, when tested in animal models of disease" 08/20/1999 - "Yersinia pestis, the causative organism of plague, produces V antigen (LcrV), a bifunctional protein with regulatory and virulence roles that has been shown to be highly protective against a plague challenge" 05/01/1997 - "Expression of the Yersinia pestis capsular antigen (F1 antigen) on the surface of an aroA mutant of Salmonella typhimurium induces high levels of protection against plague." 08/01/1995 - "These results indicate that V antigen should be a major component of an improved vaccine for plague." 05/15/2006 - "Protection against virulent plague challenge by the parenteral and aerosol routes was afforded by a single administration of microencapsulated Caf1 and LcrV antigens from Yersinia pestis in BALB/c mice" Order ALL the reference details at left...
2.	VaccinesIBA 03/24/2006 - "Yersinia pestis, the causative agent of plague, is an extremely virulent bacterium but there are no approved vaccines for protection against it" 06/01/2006 - "To aid the development of safe and effective pneumonic plague vaccines, we are deciphering mechanisms used by the immune system to protect against lethal pulmonary Y" 06/01/2006 - "The identification of Yersinia pestis as a potential bioterrorism agent and the emergence of antibiotic-resistant strains have highlighted the need for improved vaccines and treatments for plague" 04/01/2004 - "The model provides a means to directly assess the efficacy of new vaccines to prevent naturally acquired bubonic plague and to study events at the vector-host interface that lead to dissemination and disease." 03/14/2005 - "There are no approved vaccines for protection against pneumonic plague, but a Y" Order ALL the reference details at left...
3.	Streptomycin (Streptomycin Sulfate)FDA Link 02/15/2005 - "Streptomycin is the first-line antibiotic for plague treatment" 03/01/2004 - "Streptomycin, an antimicrobial with limited availability, is the treatment of choice for plague, a fulminating and potentially epidemic disease that poses a bioterrorism concern" 01/01/2001 - "pestis strain with high-level resistance to streptomycin, isolated from a human case of bubonic plague in Madagascar" 05/01/1997 - "Twenty-four deaths were related to plague, but early treatment with streptomycin has confirmed its effectiveness insofar as the case-farality ratio was only 8.7% among confirmed and presumptive cases admitted to hospital" 06/01/1995 - "The use of streptomycin in the therapeutic doses was not efficient in the animals whose blood specimens of 1 cm3 contained 4.10(4) or more plague microbes by the moment when the treatment was started." Order ALL the reference details at left...
4.	Ciprofloxacin (Cipro)FDA LinkGeneric 02/15/2003 - "There are no previous reports of plague being successfully treated with ciprofloxacin" 04/01/1996 - "Ciprofloxacin may therefore be a useful antibiotic to consider for the treatment of plague." 02/01/1996 - "The in vitro and in vivo experiments demonstrated that ciprofloxacin had an antitoxic action on lipopolysaccharide (LPS) and the plague microbe toxin" 02/15/2003 - "A case of plague successfully treated with ciprofloxacin and sympathetic blockade for treatment of gangrene." 02/15/2003 - "A critically ill patient with septicemic plague and peripheral gangrene was treated successfully with ciprofloxacin" Order ALL the reference details at left...
5.	Anti-Bacterial Agents (Antibiotics)IBA 02/01/1990 - "Because the child lived in a plague-endemic area of the southwestern United States, antibiotics effective against Yersinia pestis were administered rapidly" 01/01/2006 - "Synergistic action of some antibacterial agents in studies on albino mice with experimental plague caused by Fr- phenotype strain of the plague microbe]" 03/28/2007 - "The plague, the alarm and antibiotics: re-reading of a press release]" 01/01/2007 - "Mortality from plague is high if not treated with the proper antibiotics within 18-24 hours after onset of symptoms" 11/01/2006 - "Treatment of plague: promising alternatives to antibiotics." Order ALL the reference details at left...
6.	Rifampin (Rifampicin)FDA LinkGeneric 06/01/1995 - "The study showed that in a dose of 25 mg/kg rifampicin was highly efficient in the treatment of the albino mice with experimental glandular plague when the drug was administered either parenterally or orally for 7 days (100-percent survival)" 06/01/1995 - "The results made it possible to recommend rifampicin injections in the treatment of the most severe forms of pneumonic plague." 06/01/1995 - "Comparative effectiveness of rifampicin for parenteral administration and internal dose in the treatment of experimental plague in albino mice]" 04/01/1994 - "The experimental data indicated that the rifampicin or quinolone monotherapy required a caution and the combined etiotropic therapy was more advantageous since it decreased the risk of the complications due to the drug resistant virulent variants of the plague microbe forming during the treatment." 04/01/1994 - "A comparative study of the virulence of the clones in the population of the initial strains of the plague microbe and the cultures of the Rifr and Nalr mutants revealed that the predominating majority of the variants resistant to rifampicin and the quinolone preserved their high virulence" Order ALL the reference details at left...
7.	Doxycycline (Vibramycin)FDA LinkGeneric 01/01/2006 - "Doxycycline appears to show comparable minimum inhibitory concentrations to those of the fluoroquinolone class in most clinical and in vitro studies, perhaps with the exception of inhalation plague" 08/01/1993 - "Effectiveness of doxycycline in experimental plague]" 11/01/1992 - "The use of the daily maximum permissible doses of doxycycline (50 to 100 mg/kg a day) for 10 days in treatment of albino mice infected with the strain Fra- did not provide animal survival at the level higher than 60 to 70 per cent while the survival rate in the animals infected with the strain Fra+ of the plague microbe and treated according to the same scheme amounted to 90-100 per cent" 11/01/1992 - "Doxycycline in the prevention of experimental plague induced by plague microbe variants]" 08/01/1993 - "The high efficacy of doxycycline in the treatment of the albino mice with experimental plague infection was confirmed by the pathohistological findings" Order ALL the reference details at left...
8.	Proteins (Proteins, Gene)IBA 03/01/1999 - "Protective efficacy of recombinant Yersinia outer proteins against bubonic plague caused by encapsulated and nonencapsulated Yersinia pestis." 11/01/2008 - "Yersinia pestis, the bacterial agent of plague, secretes several proteins important for pathogenesis or host protection" 03/28/2008 - "The plague-causing bacterium Yersinia pestis utilizes a type III secretion system to deliver effector proteins into mammalian cells where they interfere with signal transduction pathways that mediate phagocytosis and the inflammatory response" 05/15/2007 - "The pathogenicity of the plague agent Yersinia pestis is largely due to the injection of effector proteins that potently block immune responses into host cells through a type III secretion apparatus" 11/01/2006 - "Identification of critical amino acid residues in the plague biofilm Hms proteins." Order ALL the reference details at left...
9.	Plague VaccineIBA 11/01/1996 - "This work demonstrates that a subunit plague vaccine formulated for human use provides significant protection against bubonic plague caused by an F1- strain (C12) or against substantial aerosol challenges from either F1+ (CO92) or F1-(C12) Y" 04/01/1977 - "The authors present the results of experimental studies on guinea pigs of the dynamics of plague immunity formation after a single inhalation immunization of the animals with live plague vaccine" 10/01/2007 - "These findings suggested that the plague F1-V subunit vaccine is promising for the next plague vaccine." 01/01/1999 - "In addition, the ratio of tissue culture infectious doses to genome copies of duck plague vaccine virus from infected duck embryo cells was determined to be 1:100, making the PCR assay 20 times more sensitive than tissue culture for detecting duck plague virus" 01/01/1995 - "Early protection of animals, immunized by a recombinant plague vaccine, from experimental plague]" Order ALL the reference details at left...
10.	AntibodiesIBA 05/01/2002 - "Treating the bacteria with either rabbit polyclonal anti-V antibodies (R anti-V) or monoclonal antibody (MAb) 7.3, antibodies specific for V and protective against plague in vivo, protected J774.A1 cells from Y" 12/01/2008 - "In addition, passive immunization studies showed that specific antibodies of macaques immunized with rLcrV, rV10, or rF1, either alone or in combination, conferred protection against bubonic plague challenge in mice" 02/01/1964 - "III. THE SERUM ANTIBODIES OF CURED PLAGUE PATIENTS.]" 10/01/2003 - "The present study aims to generate anti-F1 antibodies in mice of different genetic background and to compare antibody profile, isotype distribution and avidity measurement in sera to observe the pattern of immune response as a strategy to develop F1-based immunogen for plague" 05/01/2001 - "Our survey of mammals and fleas arose as a result of an outbreak of bubonic plague at an usually low altitude in the Ikongo district (Madagascar), while a previous study had found anti-F1 antibodies in an endemic hedgehog" Order ALL the reference details at left...

Therapies and Procedures

1.	Drug Therapy (Chemotherapy) 01/01/2004 - "Drug therapy in the official danish plague instructions, 1619-1709." 01/01/2002 - "Drug therapy in the official Danish plague instructions, 1619-1709." 10/01/1998 - "Serious consequences caused by drug-drug interactions continue to plague contemporary pharmacotherapy" 03/01/1997 - "In recent times it has waxed to become the feared White Plague of the eighteenth and nineteenth centuries and waned under the impact of effective chemotherapy until its elimination seemed possible by the early twenty-first century" 05/01/1953 - "The chemotherapy of experimental plague in the primate host." Order ALL the reference details at left...
2.	Microspheres (Microsphere) 01/03/2000 - "Generation of protective immune responses to plague by mucosal administration of microsphere coencapsulated recombinant subunits." 12/01/1998 - "We conclude that introduction of biodegradable microspheres containing the F1 and V sub-units into to the upper or lower respiratory tract engenders immune responses of a magnitude comparable with that induced by parenteral immunisation, and may present a means of protecting individuals from plague." 04/01/1998 - "Humoral immunity to plague was improved further, resulting in 80% protection from challenge, if a relatively high dose (10 micrograms) of cholera toxin B subunit was added to the microsphere suspension prior to intra-nasal delivery" 12/01/1982 - "Black bears (Ursus americanus) from 3 geographic areas of California were tested for antibodies against agents of 6 zoonotic diseases: toxoplasmosis (indirect hemagglutination), Q fever (microagglutination), trichinosis (latex particle agglutination), botulism (passive hemagglutination), leptospirosis (plate agglutination), and plague (enzyme-linked immunosorbent assay)" 04/01/1998 - "Intra nasal administration of poly-lactic acid microsphere co-encapsulated Yersinia pestis subunits confers protection from pneumonic plague in the mouse." Order ALL the reference details at left...
3.	Hematopoietic Stem Cell Transplantation 01/01/2007 - "Relapse and nonrelapse mortality continue to plague the outcome of hematopoietic stem cell transplantation (HSCT) even when undertaken in complete remission (CR)" Order ALL the reference details at left...
4.	Percutaneous Coronary Transluminal Angioplasty (PTCA) 01/01/1994 - "High restenosis rates continue to plague the overall efficacy of percutaneous transluminal coronary balloon angioplasty (PTCA)" Order ALL the reference details at left...
5.	Balloon Angioplasty (Angioplasty, Transluminal) 07/01/1993 - "Several individual devices in each category are in active clinical investigation and appear to provide safe and effective treatment for many problems that have continued to plague conventional balloon angioplasty" Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Plague

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 76 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>